STOCK TITAN

HYPERFINE - HYPR STOCK NEWS

Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.

About Hyperfine, Inc. (Nasdaq: HYPR)

Hyperfine, Inc. is a pioneering medical device company dedicated to transforming the landscape of diagnostic imaging through innovation and accessibility. The company has developed the Swoop® Portable MR Imaging System, the first FDA-cleared, portable, ultra-low-field magnetic resonance imaging (MRI) system. Designed to address the limitations of traditional MRI technology, the Swoop® system provides a cost-effective, portable, and user-friendly solution that brings imaging directly to the patient's bedside. This groundbreaking technology is particularly valuable in critical care settings such as neurointensive care units, emergency departments, and pediatric wards, where immediate access to diagnostic imaging can significantly impact clinical decision-making.

Core Business Model

Hyperfine generates revenue through two primary channels: device sales and subscription-based services. Device sales encompass the purchase of the Swoop® system, while subscription services include bundled offerings such as software updates, maintenance, and technical support. This dual revenue model ensures a steady income stream while encouraging long-term customer relationships. The Swoop® system's affordability—costing less than the annual service contract for many conventional MRI systems—further enhances its appeal to healthcare providers operating within budget constraints.

Innovative Technology and Clinical Relevance

The Swoop® Portable MR Imaging System is a technological breakthrough in the medical imaging industry. Unlike traditional MRI systems that require specialized facilities and high operational costs, the Swoop® system is portable, easy to operate, and can be powered by a standard electrical outlet. Controlled via an Apple iPad®, the system delivers high-quality images within minutes, enabling timely and informed clinical decisions. Its ultra-low-field imaging technology is designed to complement, rather than replace, stationary MRI systems, offering a flexible and scalable solution for diverse clinical environments.

Market Position and Competitive Landscape

Hyperfine operates within the highly competitive medical imaging market, which includes established players offering traditional MRI systems. However, the company differentiates itself through its focus on portability, accessibility, and cost-efficiency. By addressing the logistical and financial barriers associated with conventional MRI technology, Hyperfine is uniquely positioned to serve underserved markets, including rural healthcare facilities and resource-limited settings. The Swoop® system's ease of use—requiring less than 30 minutes of training—further enhances its adoption potential among clinicians and healthcare providers.

Global Reach and Regulatory Approvals

Hyperfine has achieved significant milestones in regulatory approvals, with the Swoop® system receiving FDA clearance in the United States, as well as certifications in Canada, Australia, the United Kingdom, the European Union, and New Zealand. These approvals underscore the system's clinical validity and open pathways for international market expansion, enabling Hyperfine to address a global need for accessible diagnostic imaging.

Significance in the Healthcare Industry

The Swoop® system represents a paradigm shift in diagnostic imaging, making MRI technology accessible to a broader range of patients and healthcare providers. Its portability and affordability are particularly impactful in emergency and critical care settings, where timely imaging can be life-saving. By complementing traditional MRI systems, Hyperfine is redefining the neuroimaging workflow, enhancing efficiency, and improving patient outcomes.

Conclusion

Hyperfine, Inc. is at the forefront of innovation in medical imaging, addressing critical gaps in accessibility and cost-effectiveness. Through its Swoop® Portable MR Imaging System, the company is not only transforming the way diagnostic imaging is delivered but also setting new standards for portability, ease of use, and clinical relevance. As a disruptive force in the healthcare industry, Hyperfine continues to make strides in democratizing medical imaging, bringing life-saving technology to patients anytime, anywhere.

Rhea-AI Summary
Hyperfine, Inc. (HYPR) presented seventeen abstracts at the ISMRM annual meeting showcasing the potential of their portable MR imaging system, Swoop®, in aiding physicians with screening and monitoring for Alzheimer’s and multiple sclerosis biomarkers. The company aims to revolutionize brain imaging with their FDA-cleared technology, demonstrating its effectiveness across various clinical conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) enrolls first Alzheimer's patients in CARE PMR study to assess the clinical utility of Swoop® Portable MR Imaging® system in detecting ARIA events in patients receiving amyloid-targeting therapy. The study aims to simplify workflow and improve care efficiency in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) reported strong growth in 2023, achieving $11.03 million in revenues, up 62% from 2022. The company sold 37 Swoop® systems in 2023, with a net loss of $44.24 million. Hyperfine received multiple certifications, launched new programs, and reduced cash burn to extend cash runway. Fourth quarter 2023 revenues were $2.69 million, up 89% from the previous year. The company sold seven Swoop® systems in Q4 2023, with a net loss of $10.68 million. Management expects 2024 revenue to reach $12 to $15 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
Rhea-AI Summary
Hyperfine, Inc. (HYPR) showcases the first FDA-cleared portable MR brain imaging system to The Princess Royal, highlighting its use in testing MR access disparities in low- and medium-resource countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.66%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) will report financial results for Q4 and full year 2023 on March 21, 2024. The company, known for its portable MR brain imaging system, Swoop®, has redefined brain imaging technology. The conference call will be hosted by management at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live webcast on Hyperfine's Investors page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Hyperfine, Inc. (HYPR) to present at Oppenheimer Healthcare MedTech & Services Conference with a focus on their FDA-cleared portable MR brain imaging system, the Swoop® system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
conferences
Rhea-AI Summary
Hyperfine, Inc. (HYPR) collaborates with Athletic Heart to provide portable brain imaging screenings to professional athletes, starting with retired basketball players. The partnership aims to enhance brain health insights for athletes through the use of the Swoop® Portable MR Imaging® system. The inaugural event took place at the 2024 All-Star game in Indianapolis, showcasing the commitment to accessible and comprehensive medical care for athletes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announced the presentation of four abstracts at the 2024 International Stroke Conference, showcasing the clinical utility and applications of portable ultra-low-field MR imaging. The Swoop® system aims to transform the diagnosis and treatment of acute ischemic stroke. The company also provided an update on the enrollment progress of the ACTION PMR study, which aims to integrate brain imaging with the Swoop® system into the stroke diagnosis and treatment workflow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) has obtained CE and UKCA approval for the eighth generation of Swoop® system software, which includes AI-powered features such as DWI denoising. The software has been well-received by users, improving image quality and workflow efficiencies. With international certifications, the company is poised for global expansion, aiming to bring the Swoop® system to a broader market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
AI
Rhea-AI Summary
Hyperfine, Inc. (Nasdaq: HYPR) announces that three scientific sessions highlighting ultra-low-field imaging data will be presented at the Radiological Society of North America (RSNA) 2023 Annual Meeting. The studies analyzed how portable MR brain imaging may assist in the diagnosis and management of neurological conditions in critical care settings, showcasing the potential of portable ultra-low-field brain imaging to improve brain health. The sessions will cover topics such as longitudinal relaxivity estimation of contrast agents, generative adversarial network approach for low-field to high-field image translation, and preliminary results from a single-center retrospective study in the neurocritical care setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
none

FAQ

What is the current stock price of HYPERFINE (HYPR)?

The current stock price of HYPERFINE (HYPR) is $0.93 as of March 3, 2025.

What is the market cap of HYPERFINE (HYPR)?

The market cap of HYPERFINE (HYPR) is approximately 78.2M.

What is Hyperfine, Inc. known for?

Hyperfine, Inc. is known for developing the Swoop® Portable MR Imaging System, the first portable, FDA-cleared MRI system for bedside imaging.

How does Hyperfine generate revenue?

Hyperfine generates revenue through device sales and subscription-based services for software, maintenance, and technical support.

What makes the Swoop® system unique?

The Swoop® system is portable, cost-effective, and easy to use, providing high-quality imaging directly at the patient’s bedside within minutes.

Who are Hyperfine's target customers?

Hyperfine targets healthcare providers in critical care settings, including neurointensive care units, emergency departments, and pediatric wards.

What are the regulatory approvals for the Swoop® system?

The Swoop® system has received FDA clearance in the U.S. and certifications in Canada, Australia, the UK, the EU, and New Zealand.

How does the Swoop® system complement traditional MRI systems?

The Swoop® system complements traditional MRI systems by offering a portable, accessible solution for immediate bedside imaging when stationary systems are impractical.

What challenges does Hyperfine face in the market?

Hyperfine faces challenges such as market adoption, competition from established imaging companies, and the need to continually improve image quality and clinical applicability.

How long does it take to train new users on the Swoop® system?

Training new users on the Swoop® system takes less than 30 minutes, making it highly accessible for clinicians.
HYPERFINE

Nasdaq:HYPR

HYPR Rankings

HYPR Stock Data

78.23M
56.94M
9.5%
24.35%
2.14%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
GUILFORD